AARD — Aardvark Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1774857 ·
Last close
$4.71
Market Cap
$103.08M
52W High
$17.23
52W Low
$3.35
ADV30
130,344
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -15,084,000 | -14,387,000 | 81,460,000 | 73,849,000 | 6,663,000 |
| Mar 2026 | 0 | — | -22,464,000 | -21,588,000 | 98,590,000 | 62,436,000 | 11,604,000 |
| Dec 2025 | 0 | — | -18,704,000 | -17,598,000 | 117,181,000 | 47,051,000 | 10,548,000 |
| Sep 2025 | 0 | — | -17,703,000 | -16,316,000 | 133,229,000 | 39,285,000 | 10,852,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-61,653,000
Investing CF
$97,207,000
Financing CF
$378,000
CapEx
$-10,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.21
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-137,506,000
Inventory
—
Receivables
—
ST Investments
$28,764,000
EBIT TTM
$-74,719,000
Pretax Income TTM
$-69,869,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -62,725,000 | -57,591,000 | 117,181,000 | 10,548,000 | 106,633,000 | -54,172,000 |
| Dec 2024 | 0 | -22,668,000 | -20,588,000 | 77,507,000 | 132,150,000 | -54,643,000 | -18,087,000 |
| Dec 2023 | 0 | -6,653,000 | -7,208,000 | 10,536,000 | 45,338,000 | -34,802,000 | -5,824,000 |
| Dec 2022 | 0 | -10,874,000 | -13,564,000 | 16,757,000 | 44,680,000 | -27,923,000 | -10,543,000 |
TTM Snapshot
Revenues TTM
$4,853,000
NetIncome TTM
$-69,869,000
OpCashFlow TTM
—
Assets (Latest)
$98,590,000
Forward EPS
$-2.78
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMUX | IMMUNIC, INC. | $103.15M | $7.56 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $101.93M | $5.27 | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $104.58M | $6.98 | — |
| ANIX | Anixa Biosciences Inc | $101.16M | $2.91 | — |
| KZIA | KAZIA THERAPEUTICS LTD | $100.79M | $8.82 | — |
News headlines (Yahoo Finance, 1h cache)
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
2026-10-08 12:00 · Yahoo
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:05 · Yahoo
Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ...
2026-08-17 17:31 · Yahoo
Several Insiders Invested In Aardvark Therapeutics Flagging Positive News
2026-05-28 10:14 · Yahoo
FDA hold puts Aardvark Prader-Willi drug in limbo
2026-05-15 11:58 · Yahoo
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
2026-05-14 20:01 · Yahoo
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-07 12:00 · Yahoo
Top Midday Decliners
2026-05-15 18:20 · Yahoo
Discover 3 Promising Penny Stocks With Market Caps Over $100M
2026-04-17 12:05 · Yahoo
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-11 20:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.